Moxonidine Eg (Moxonidine)

Moxonidine selectively stimulates imidazoline I1 receptors in the brainstem, reducing sympathetic nervous system activity. This leads to decreased peripheral vascular resistance and lower cardiac output, ultimately lowering arterial blood pressure.

The dosage of Moxonidine Eg is determined by the prescribing healthcare professional based on the individual’s condition, response, and any co‑existing medical issues. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for moxonidine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Moxonidine differs from many antihypertensives because it targets central imidazoline I1 receptors rather than angiotensin‑converting enzyme or calcium channels. This mechanism can provide effective blood‑pressure control with a distinct side‑effect profile, making it an alternative for patients who need a different therapeutic approach.

Moxonidine Eg should be stored at room temperature, below 25 °C, in its original container to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date.

Moxonidine Eg is taken orally, usually with or without food, as directed by the prescriber. The tablets should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include severe hypotension, bradycardia, allergic reactions such as rash or angioedema, and rare liver enzyme elevations. Patients should seek immediate medical attention if they experience fainting, rapid heartbeat, or signs of an allergic response.

Moxonidine Eg is contraindicated in patients with known hypersensitivity to moxonidine or any component of the formulation. Caution is advised for individuals with severe renal impairment, uncontrolled heart failure, or those taking multiple central antihypertensive agents.